Navigation Links
ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
Date:4/23/2008

p>

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

About Urokinase

In 2006, ImaRx acquired urokinase and all related assets, including approximately a four-year supply of inventory as well as cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market, where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals.

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients.

Forward Looking Statements

Statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks related to our ability to successfully commercialize urokinase and other important risks relating to the Company's business, prospects, financial condition and results of operations that are discussed in the Section titled "Risk Factors" in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2007, which has been filed with the SEC.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

sephra
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
2. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx to Report Corporate Updates and 4Q07 Financial Results
5. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
6. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... May 21 Martek Biosciences,Corporation (Nasdaq: MATK ) ... UBS Global Generic and Specialty Pharmaceuticals Conference in,London. The ... at the Waldorf,Hilton, Aldwych, London. Steve Dubin, CEO will ... EDT (2:00 p.m. London Time)., Interested parties may ...
... Still River Systems announces,the successful development and operation ... of the development of its Monarch250(TM) proton,therapy system. ... conclusively,demonstrates that cyclotrons at this high field strength ... By increasing the operating,magnetic field, Still River Systems ...
... N.J., May 21 Aton Pharma, Inc., a ... signed a,marketing and distribution agreement with PharmaLink Asia ... into several countries in Asia and,Australia., "This ... we execute,our mission to expand access to our ...
Cached Biology Technology:Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Aton Pharma Announces Distribution Partnership in the Asia Pacific Region 2
(Date:7/23/2014)... , July 24, 2014 Pfenex Inc. (NYSE ... offering of 8,333,333 shares of its common stock at a ... Pfenex has granted the underwriters a 30-day option to purchase ... initial public offering price. The shares are expected to begin ... the symbol "PFNX". William Blair & ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... crow and the pitcher, a thirsty bird happens upon a ... it, he finds the water level out of his reach. ... drops pebbles into it one at a time ... his fill. , Highlighting the value of ingenuity, the fable ... brute force. It also characterizes crows as pretty resourceful problem ...
Breaking Biology News(10 mins):Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... Researchers have identified a gene that appears to increase a ... type of Alzheimer,s disease. The research will be presented as ... of Neurology,s 62nd Annual Meeting in Toronto, April 10 ... six. "Only recently have common variants in genes ...
... who co-piloted the historic 1960 deep-sea voyage of the Trieste, will ... on at 10 a.m. April 15 at the U.S. Navy Museum ... to have visited the Challenger Deep the deepest part of ... navigating the bathyscaphe (deep submergence vehicle) Trieste 35,810 feet down to ...
... 13, 2010 -- Two chemists at The Scripps Research Institute have ... that turns itself on or off as it detects metallic ions ... the April 19, 2010 issue of the International Edition of the ... tool for controlling tiny reactions in the test tube, and it ...
Cached Biology News:New gene associated with increased risk of Alzheimer's disease 2New nano-tool synthesized at Scripps Research Institute 2
... Visualizer DX's sensitivity of DNA detection has been ... in an agarose gel can be detected > ... can be purified by organic solvent extraction or ... kits worked well.) DNA excised from agarose ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Small space saving design - ideal for personal ... models: , - 3D gyratory action SSM3 , ... speed control and built-in timer , Optional tier system ... ideal where gentle mixing is required, either on the ...
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
Biology Products: